Trials / Conditions / Relapsed or Refractory Peripheral T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell Lymphoma

7 registered clinical trials studyying Relapsed or Refractory Peripheral T-cell Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refrac NCT07288814	Sun Yat-Sen University Cancer Center	Phase 1 / Phase 2
Recruiting	Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL) NCT05833724	Great Novel Therapeutics Biotech & Medicals Corporation	Phase 2
Unknown	A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma NCT04108325	Shanghai YingLi Pharmaceutical Co. Ltd.	Phase 1
Unknown	Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT04329130	Sun Yat-sen University	Phase 2
Completed	Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) NCT04105010	Dizal Pharmaceuticals	Phase 1 / Phase 2
Completed	Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma NCT03356678	Samsung Medical Center	—
Completed	Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Resp NCT02464228	Kura Oncology, Inc.	Phase 2